Frailty in Hepatocellular Carcinoma: An Unsettled Clinical Challenge

Area of Science:

• Geriatrics
• Oncology
• Hepatology

Background:

• Frailty is a clinical syndrome recognized across medical fields, initially in geriatrics.
• Performance Status (PS) traditionally guides cancer treatment, but comprehensive frailty assessment is gaining importance due to aging populations and evolving treatments.
• In cirrhosis patients, frailty can appear earlier, with the Liver Frailty Index (LFI) validated for liver transplant candidates.

Purpose of the Study:

• To highlight the emerging role of frailty assessment in hepatocellular carcinoma (HCC) patient care.
• To address the limited evidence and lack of standardized tools for frailty in HCC treatment decisions.

Main Methods:

• Review of existing literature on frailty assessment tools in geriatrics, oncology, and hepatology.
• Analysis of the applicability of current frailty measures in the context of HCC.
• Identification of gaps in standardized frailty assessment for HCC patient stratification.

Main Results:

• Frailty is prevalent in HCC patients due to cirrhosis and tumor burden.
• Existing tools like PS and LFI offer insights but are not fully optimized for HCC.
• Evidence on frailty's impact on HCC treatment decisions is limited.

Conclusions:

• Frailty is a significant factor in HCC patients that requires further investigation.
• Development of standardized frailty assessment tools is essential for optimizing HCC treatment strategies.
• Improved frailty assessment can enhance patient stratification and therapeutic allocation in HCC management.